

MEDICAL LABORATORY EVALUATION

PARTICIPANT SUMMARY

2 • 0 • 0 • 8

Please see the corresponding US participant summary for any statistics not represented in this supplement.



Total Commitment to Education and Service
Provided by ACP Services, Inc.

**International Data Supplement
MLE – M2**

Table of Contents

2008 Evaluation Criteria	3
---------------------------------------	----------

Coagulation

Prothrombin Time	4
International Normalized Ratio (INR)	6
Activated Partial Thromboplastin Time	8
Fibrinogen	9

Urinalysis

Urinalysis Dipstick	10
Specific Gravity	10
pH	11
Protein	11
Glucose or Reducing Substance	12
Ketones.....	12
Bilirubin	13
Urobilinogen.....	13
Blood or Hemoglobin	14
Leukocyte Esterase	14
Nitrite	15
Microalbumin (Dipstick Only)	15
Urine hcG	15

Microbiology

Antimicrobial Susceptibility Testing	16
Parasitology (PA Specimens)	17
Parasitology (FP Specimens)	18

Immunology

Syphilis Serology	20
VDRL Slide	20
VDRL Slide (Titer).....	20
MHA-TP	21
FTA-ABS.....	21
RPR	21
RPR (Titer).....	22

Viral Markers	23
Anti-HBc.....	23
Anti-HIV	24
HAV	25
HBeAg	26
HBsAb.....	27
HBsAg.....	28
HCV	29

Chemistry

Blood Gases	30
--------------------------	-----------

2008 Evaluation Criteria

The evaluation criteria used in the 2008 MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

Qualitative

For qualitative procedures, evaluation is based on participant consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Antimicrobial Susceptibility Testing	80% Consensus
Microalbumin (Semi-Quantitative)	80% Consensus
Parasite Identification	80% Consensus
Syphilis Serology	80% Consensus
Urine Dipstick	80% Consensus
Urine hCG	80% Consensus
Viral Markers	80% Consensus

Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 5 or more laboratories. Acceptable performance is established based on a target value \pm the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on pages 39-40 under the heading "Acceptable Ranges for Quantitative Results."

Activated Partial Thromboplastin Time	\pm 15 percent
Calcium, Ionized	\pm 3 SD
Chloride	\pm 5%
Fibrinogen	\pm 20 percent
International Normalized Ratio	\pm 3 SD
pCO ₂	\pm 5 mmHg or 8% *
pH	\pm 0.04
pO ₂	\pm 3 SD
Potassium	\pm 0.5 mmol/L
Prothrombin Time	\pm 15 percent
Sodium	\pm 4.0 mmol/L
Specific Gravity	\pm 0.010

*Whichever is greater

PROTHROMBIN TIME (seconds)**Specimen CG-10**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	159	13.47	2.23	16.6	13.5
bioMerieux Simplastin Excel S					
bioMerieux Thrombotimer	5	17.70	1.04	5.9	17.0
All Coagulation Instruments	18	17.53	1.00	5.7	17.4
Dade Innovin					
Sysmex CA-1000/1500	6	11.28	0.31	2.7	11.4
Sysmex CA-500	6	11.52	1.43	12.4	11.1
All Coagulation Instruments	11	11.13	0.32	2.8	11.1
Dade Thromborel S					
Sysmex CA-500	7	13.34	0.92	6.9	13.0
All Coagulation Instruments	21	13.30	0.92	6.9	13.3
Diag Stago STA Neoplastine CI+					
RAL Clot-SP	10	14.87	0.43	2.9	14.9
All Coagulation Instruments	11	14.94	0.47	3.1	14.9
HUMAN HemoStat Thromboplastin - SI					
All Coagulation Instruments	17	14.13	1.14	8.1	14.1
IL TEST PT-FIB Recombinant					
IL ACL, all models	38	11.09	0.52	4.6	11.1
PH/CMS Thromboplastin-DS					
All Coagulation Instruments	5	14.22	0.69	4.8	14.5
TEClot PT					
Coatron M2 / M4	16	14.08	1.17	8.3	14.0
Wiener Lab Soluplastin					
All Coagulation Instruments	6	14.75	1.15	7.8	15.3

PROTHROMBIN TIME–INTERNATIONAL NORMALIZED RATIO (INR)

Specimen CG-10

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	159	1.11	0.14	12.5	1.1
bioMerieux Simplastin Excel S					
bioMerieux Thrombotimer	5	1.24	0.15	12.2	1.3
All Coagulation Instruments	19	1.24	0.15	12.4	1.2
Dade Innovin					
Sysmex CA-1000/1500	6	1.10	0.06	5.7	1.1
Sysmex CA-500	6	1.07	0.10	9.7	1.1
All Coagulation Instruments	12	1.08	0.08	7.7	1.1
Dade Thromborel S					
Sysmex CA-500	8	1.15	0.09	8.1	1.2
All Coagulation Instruments	21	1.15	0.08	6.5	1.2
Diag Stago STA Neoplastine CI+					
RAL Clot-SP	10	1.16	0.07	6.0	1.2
All Coagulation Instruments	11	1.18	0.10	8.3	1.2
HUMAN HemoStat					
Thromboplastin - SI					
All Coagulation Instruments	17	1.08	0.08	7.7	1.1
IL TEST PT-FIB Recombinant					
IL ACL, all models	37	0.97	0.08	8.6	1.0
PH/CMS Thromboplastin-DS					
All Coagulation Instruments	5	1.10	0.14	12.9	1.0
TEClot PT					
Coatron M2 / M4	17	1.22	0.23	18.9	1.2
Wiener Lab Soluplastin					
All Coagulation Instruments	6	1.18	0.08	6.4	1.2

ACTIVATED PARTIAL THROMBOPLASTIN (seconds)

Specimen CG-10

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	146	35.8	4.0	11.2	36
bioMerieux autoAPTT Reagent					
bioMerieux Thrombotimer	7	37.7	2.1	5.7	38
All Coagulation Instruments	21	36.5	4.2	11.5	38
Dade Actin FS					
All Coagulation Instruments	5	37.2	5.4	14.5	39
Dade Actin FSL					
Sysmex CA-1000/1500	5	32.2	1.3	4.0	33
Sysmex CA-500	5	32.0	1.2	3.8	32
All Coagulation Instruments	16	31.7	1.4	4.4	32
Dade Actin					
Sysmex CA-500	6	39.7	5.1	12.8	40
All Coagulation Instruments	11	39.4	4.4	11.1	40
HUMAN HemoStat aPTT - EL					
bioMerieux Thrombolyzer Compact X/XR	5	35.0	3.4	9.7	35
All Coagulation Instruments	20	33.9	3.4	10.2	35
IL TEST APTT-SP					
IL ACL, all models	35	37.3	2.7	7.3	37
All Coagulation Instruments	36	37.3	2.7	7.2	37
TEClot APTT					
Coatron M2 / M4	15	33.7	4.0	11.9	34

FIBRINOGEN (mg/dL)

Specimen CG-6

Specimen CG-7

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	76	269.7	33.7	12.5	264	71	340.2	48.4	14.2	340
bioMerieux Fibriquik										
All Coagulation Instruments	5	261.8	20.2	7.7	271	5	313.0	41.0	13.1	336
Dade Fibrinogen Set										
Sysmex CA-1000/1500	6	259.7	8.2	3.2	262	6	319.2	8.5	2.7	325
Sysmex CA-500	11	263.5	25.3	9.6	256	10	298.7	40.3	13.5	299
All Coagulation Instruments	20	261.2	21.8	8.3	256	19	307.7	30.7	10.0	310
IL TEST PT-FIB Recombinant										
IL ACL, all models	30	276.4	28.1	10.2	273	30	363.4	35.8	9.8	358

Specimen CG-8

Specimen CG-9

All Method	74	118.4	20.1	17.0	115	72	297.1	47.6	16.0	295
bioMerieux Fibriquik										
All Coagulation Instruments	5	93.2	19.5	20.9	106	4	-	-	-	284
Dade Fibrinogen Set										
Sysmex CA-1000/1500	6	101.8	6.1	6.0	101	6	258.3	14.7	5.7	264
Sysmex CA-500	11	110.3	13.8	12.5	110	10	263.7	23.8	9.0	265
All Coagulation Instruments	20	107.8	13.1	12.2	109	19	264.9	20.6	7.8	265
IL TEST PT-FIB Recombinant										
IL ACL, all models	30	125.4	17.5	13.9	124	30	307.8	32.9	10.7	305

FIBRINOGEN (mg/dL)

Specimen CG-10

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method bioMerieux Fibriquik	71	491.1	87.6	17.8	502
All Coagulation Instruments Dade Fibrinogen Set	4	-	-	-	487
Sysmex CA-1000/1500	6	395.3	21.5	5.4	413
Sysmex CA-500	9	418.4	43.7	10.4	421
All Coagulation Instruments IL TEST PT-FIB Recombinant	18	412.9	37.7	9.1	413
IL ACL, all models	29	524.0	42.7	8.1	515

Urinalysis

URINALYSIS DIPSTICK-SPECIFIC GRAVITY

Specimen UA-2

<u>Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Refractive Index Methods	6	1.0203	0.0008	0.1	1.020
All Method	164	1.0145	0.0053	0.5	1.015
Arkray Aution Jet	5	1.0260	0.0022	0.2	1.025
Arkray Aution Sticks	11	1.0207	0.0053	0.5	1.021
Bayer Clinitek 50	7	1.0100	0.0000	0.0	1.010
Bayer Clinitek 500	14	1.0143	0.0027	0.3	1.015
Bayer Clinitek Atlas	5	1.0200	0.0000	0.0	1.020
Bayer Reagent Strips	11	1.0118	0.0025	0.2	1.010
Roche (BMC) Chemstrips	23	1.0117	0.0036	0.4	1.010
Roche Miditron	5	1.0130	0.0027	0.3	1.015
Roche Urisys	26	1.0157	0.0052	0.5	1.015
UriScan Reagent Strips	24	1.0125	0.0029	0.3	1.010

URINALYSIS DIPSTICK–pH

Specimen UA-2

Participant Results

<u>Method</u>	<u>3.5 or less</u>	<u>4.0</u>	<u>5.0</u>	<u>5.5</u>	<u>6.0</u>	<u>6.5</u>	<u>7.0</u>	<u>7.5</u>	<u>8.0</u>	<u>8.5</u>	<u>9.0</u>
ALL METHODS	-	-	-	-	-	1	13	68	88	-	-
Arkray Aution Jet	-	-	-	-	-	-	-	5	-	-	-
Arkray Aution Sticks	-	-	-	-	-	-	-	9	2	-	-
Arkray PocketChem UA	-	-	-	-	-	-	-	3	-	-	-
Bayer Clinitek 10 / 100	-	-	-	-	-	-	-	1	-	-	-
Bayer Clinitek 50	-	-	-	-	-	-	-	6	1	-	-
Bayer Clinitek 500	-	-	-	-	-	-	1	4	9	-	-
Bayer Clinitek Atlas	-	-	-	-	-	-	-	5	-	-	-
Bayer Clinitek Status	-	-	-	-	-	-	-	1	-	-	-
Bayer Reagent Strips	-	-	-	-	-	1	1	6	3	-	-
Iris Diagnostics Aution Max AX-4280	-	-	-	-	-	-	-	1	-	-	-
Iris Diagnostics iChem 100	-	-	-	-	-	-	-	-	3	-	-
Roche (BMC) Chemstrips	-	-	-	-	-	-	3	-	21	-	-
Roche (BMC) Criterion Analyzer	-	-	-	-	-	-	-	-	3	-	-
Roche (BMC) Mini UA	-	-	-	-	-	-	-	-	1	-	-
Roche Mditron	-	-	-	-	-	-	-	-	5	-	-
Roche Urisys	-	-	-	-	-	-	5	-	21	-	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	-	-	-	4	-	-
UriScan Pro	-	-	-	-	-	-	-	1	-	-	-
UriScan Reagent Strips	-	-	-	-	-	-	-	20	6	-	-

URINALYSIS DIPSTICK–PROTEIN QUALITATIVE

Specimen UA-2

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>30mg/dL (1+)</u>	<u>100 mg/dL (2+)</u>	<u>300-500mg/dL (3+)</u>	<u>≥1000mg/dL (4+)</u>
ALL METHODS	165	1	1	-	1	-
Arkray Aution Jet	5	-	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-	-
Arkray PocketChem UA	3	-	-	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-	-
Bayer Clinitek 500	13	-	1	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-	-
Bayer Reagent Strips	10	-	-	-	-	-
Iris Diagnostics Aution Max AX-4280	1	-	-	-	-	-
Iris Diagnostics iChem 100	3	-	-	-	-	-
Roche (BMC) Chemstrips	24	-	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-	-
Roche (BMC) Mini UA	1	-	-	-	-	-
Roche Mditron	5	-	-	-	-	-
Roche Urisys	25	-	-	-	1	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-	-
UriScan Pro	1	-	-	-	-	-
UriScan Reagent Strips	26	-	-	-	-	-

URINALYSIS DIPSTICK–GLUCOSE OR REDUCING SUBSTANCE

Specimen UA-2

<u>Method</u>	<i>Participant Results</i>							
	<u>Negative</u>	<u>50-100 mg/dL (Trace)</u>	<u>150 mg/dL</u>	<u>250 mg/dL</u>	<u>500 mg/dL</u>	<u>1000 mg/dL</u>	<u>>1000 mg/dL</u>	<u>≥2000 mg/dL</u>
ALL METHODS	166	-	1	-	-	-	-	-
Arkray Aution Jet	5	-	-	-	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-	-	-	-
Arkray PocketChem UA	3	-	-	-	-	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-	-	-	-
Bayer Clinitek 500	13	-	1	-	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-	-	-	-
Bayer Reagent Strips	10	-	-	-	-	-	-	-
Iris Diagnostics Aution Max AX-4280	1	-	-	-	-	-	-	-
Iris Diagnostics iChem 100	3	-	-	-	-	-	-	-
Roche (BMC) Chemstrips	24	-	-	-	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-	-	-	-
Roche (BMC) Mini UA	1	-	-	-	-	-	-	-
Roche Miditron	5	-	-	-	-	-	-	-
Roche Urisys	26	-	-	-	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-	-	-	-
UriScan Pro	1	-	-	-	-	-	-	-
UriScan Reagent Strips	25	-	-	-	-	-	-	-

URINALYSIS DIPSTICK–KETONES

Specimen UA-2

<u>Method</u>	<i>Participant Results</i>				
	<u>Negative</u>	<u>Trace (5 mg/dL)</u>	<u>Small (1+, 15 mg/dL)</u>	<u>Moderate (2+, 40 mg/dL)</u>	<u>Large (3+, 80 mg/dL)</u>
ALL METHODS	2	-	1	9	158
Arkray Aution Jet	-	-	-	-	5
Arkray Aution Sticks	-	-	-	-	11
Arkray PocketChem UA	-	-	-	-	3
Bayer Clinitek 10 / 100	-	-	-	-	1
Bayer Clinitek 50	1	-	-	-	6
Bayer Clinitek 500	-	-	-	-	14
Bayer Clinitek Atlas	-	-	-	-	5
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	1	-	10
Iris Diagnostics Aution Max AX-4280	-	-	-	-	1
Iris Diagnostics iChem 100	-	-	-	-	3
Roche (BMC) Chemstrips	-	-	-	2	22
Roche (BMC) Criterion Analyzer	-	-	-	-	3
Roche (BMC) Mini UA	-	-	-	-	1
Roche Miditron	-	-	-	-	5
Roche Urisys	-	-	-	-	26
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	4
UriScan Pro	-	-	-	1	-
UriScan Reagent Strips	1	-	-	4	21

URINALYSIS DIPSTICK–BILIRUBIN

Specimen UA-2

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	167	-	-	-
Arkray Aution Jet	5	-	-	-
Arkray Aution Sticks	11	-	-	-
Arkray PocketChem UA	3	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-
Bayer Clinitek 50	7	-	-	-
Bayer Clinitek 500	14	-	-	-
Bayer Clinitek Atlas	5	-	-	-
Bayer Clinitek Status	1	-	-	-
Bayer Reagent Strips	10	-	-	-
Iris Diagnostics Aution Max AX-4280	1	-	-	-
Iris Diagnostics iChem 100	3	-	-	-
Roche (BMC) Chemstrips	24	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-
Roche (BMC) Mini UA	1	-	-	-
Roche Miditron	5	-	-	-
Roche Urisys	26	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-
UriScan Pro	1	-	-	-
UriScan Reagent Strips	26	-	-	-

URINALYSIS DIPSTICK–UROBILINOGEN

Specimen UA-2

Participant Results

<u>Method</u>	<u>0.2/Normal mg/dL</u>	<u>1.0 mg/dL</u>	<u>2.0 mg/dL</u>	<u>4.0 mg/dL</u>	<u>>8.0 mg/dL</u>
ALL METHODS	167	-	-	-	-
Arkray Aution Jet	5	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-
Arkray PocketChem UA	3	-	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-
Bayer Clinitek 500	14	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	10	-	-	-	-
Iris Diagnostics Aution Max AX-4280	1	-	-	-	-
Iris Diagnostics iChem 100	3	-	-	-	-
Roche (BMC) Chemstrips	24	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-
Roche (BMC) Mini UA	1	-	-	-	-
Roche Miditron	5	-	-	-	-
Roche Urisys	26	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Pro	1	-	-	-	-
UriScan Reagent Strips	26	-	-	-	-

URINALYSIS DIPSTICK–BLOOD/HEMOGLOBIN

Specimen UA-2

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	166	1	-	-	-
Arkray Aution Jet	5	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-
Arkray PocketChem UA	3	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-
Bayer Clinitek 500	14	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	9	1	-	-	-
Iris Diagnostics Aution Max AX-4280	1	-	-	-	-
Iris Diagnostics iChem 100	3	-	-	-	-
Roche (BMC) Chemstrips	24	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-
Roche (BMC) Mini UA	1	-	-	-	-
Roche Miditron	5	-	-	-	-
Roche Urisys	26	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Pro	1	-	-	-	-
UriScan Reagent Strips	26	-	-	-	-

URINALYSIS DIPSTICK–LEUKOCYTE ESTERASE

Specimen UA-2

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	1	-	-	6	161
Arkray Aution Jet	-	-	-	-	5
Arkray Aution Sticks	-	-	-	-	11
Arkray PocketChem UA	-	-	-	1	2
Bayer Clinitek 10 / 100	-	-	-	-	1
Bayer Clinitek 50	-	-	-	-	7
Bayer Clinitek 500	-	-	-	-	14
Bayer Clinitek Atlas	-	-	-	-	5
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	-	4	7
Iris Diagnostics Aution Max AX-4280	-	-	-	-	1
Iris Diagnostics iChem 100	-	-	-	-	3
Roche (BMC) Chemstrips	-	-	-	-	24
Roche (BMC) Criterion Analyzer	-	-	-	-	3
Roche (BMC) Mini UA	-	-	-	-	1
Roche Miditron	-	-	-	-	4
Roche Urisys	-	-	-	-	26
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	4
UriScan Pro	-	-	-	-	1
UriScan Reagent Strips	1	-	-	-	25

URINALYSIS DIPSTICK–NITRITE

Specimen UA-2

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	-	167
Arkray Aution Jet	-	5
Arkray Aution Sticks	-	11
Arkray PocketChem UA	-	3
Bayer Clinitek 10 / 100	-	1
Bayer Clinitek 50	-	7
Bayer Clinitek 500	-	14
Bayer Clinitek Atlas	-	5
Bayer Clinitek Status	-	1
Bayer Reagent Strips	-	11
Iris Diagnostics Aution Max AX-4280	-	1
Iris Diagnostics iChem 100	-	3
Roche (BMC) Chemstrips	-	24
Roche (BMC) Criterion Analyzer	-	2
Roche (BMC) Mini UA	-	1
Roche Mditron	-	5
Roche Urisys	-	25
Roche(BMC) SuperUA/ChemstripUA	-	4
UriScan Pro	-	1
UriScan Reagent Strips	-	26

URINALYSIS –MICROALBUMIN (dipstick only)

Specimen UA-2

Participant Results

<u>Method</u>	<u>Negative</u>	<u>10 mg/L(Pos)</u>	<u>20/30 mg/L</u>	<u>50 mg/L (+)</u>	<u>80 mg/L</u>	<u>100 mg/L (++)</u>	<u>150 mg/L</u>
ALL METHODS	6	4	-	-	-	-	-
Bayer Clinitek 50	-	1	-	-	-	-	-
Bayer Clinitek Microalbumin	-	1	-	-	-	-	-
Roche (BMC) Micral - 1 minute	-	1	-	-	-	-	-
Roche Urisys	1	-	-	-	-	-	-

URINALYSIS –URINE hCG

Specimen UA-2

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	12	-
Acon Laboratories	2	-
bioMerieux VIKIA hCG-D	6	-

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Specimen SUS-6

<u>Antimicrobial</u>	-----Disk Diffusion-----				-----MIC-----				<u>Acceptable (%)</u>
	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	
Amikacin	6	3	3	-	1	1	-	-	Not graded ¹
Amoxicillin/Clavulanate	4	-	-	4	28	1	-	27	93.02%
Ampicillin	5	1	-	4	24	-	-	24	95.56%
Ampicillin/Sulbactam	7	2	1	4	9	-	-	9	82.76%
Aztreonam	2	-	-	2	-	-	-	-	80.00%
Cefaclor	4	-	-	4	-	-	-	-	100%
Cefazolin	2	-	-	2	32	-	-	32	96.15%
Cefepime	2	-	-	2	1	-	-	1	85.71%
Cefotaxime	4	-	-	4	1	-	-	1	87.50%
Cefoxitin	4	-	-	4	4	1	-	3	93.33%
Ceftazidime	2	-	-	2	1	1	-	-	Not graded ¹
Ceftriaxone	3	-	-	3	2	-	-	2	Not graded ¹
Cefuroxime	4	-	-	4	2	1	-	1	Not graded ¹
Cephalothin	8	-	-	8	1	-	-	1	100%
Chloramphenicol	2	2	-	-	-	-	-	-	100%
Ciprofloxacin	13	-	-	13	36	1	-	35	92.75%
Clindamycin	14	1	-	13	35	-	-	35	95.65%
Daptomycin	-	-	-	-	2	2	-	-	100%
Doxycycline	2	2	-	-	-	-	-	-	100%
Fosfomycin	1	1	-	-	2	2	-	-	100%
Gentamicin	11	10	-	1	43	43	-	-	98.77%
Imipenem	3	1	-	2	18	1	1	16	80.65%
Levofloxacin	3	-	-	3	24	-	-	24	93.18%
Linezolid	4	4	-	-	23	23	-	-	97.62%
Meropenem	2	-	-	2	-	-	-	-	Not graded ¹
Methicillin	1	-	-	1	-	-	-	-	100%
Minocycline	-	-	-	-	2	2	-	-	100%
Nalidixic Acid	3	-	-	3	1	1	-	-	Not graded ¹
Nitrofurantoin	10	10	-	-	35	34	-	1	98.55%
Norfloxacin	9	-	-	9	6	1	-	5	90.91%
Ofloxacin	4	-	-	4	-	-	-	-	100%
Oxacillin	16	1	-	15	42	-	-	42	97.62%
Penicillin	8	-	-	8	29	-	-	29	98.25%
Piperacillin	-	-	-	-	1	1	-	-	100%
Piperacillin/Tazobactam	2	1	-	1	2	-	-	2	Not graded ¹
Quinopristin/Dalfopristin	-	-	-	-	3	3	-	-	100%
Rifampin	3	-	-	3	29	1	-	28	96.08%
Sulfisoxazole	-	-	-	-	1	1	-	-	100%
Teicoplanin	-	-	-	-	3	3	-	-	100%
Tetracycline	7	7	-	-	40	39	-	1	97.06%
Ticarcillin/Clavulanate	-	-	-	-	1	1	-	-	100%
Tobramycin	-	-	-	-	1	1	-	-	100%
Trimethoprim	3	2	-	1	4	4	-	-	88.89%
Trimethoprim/Sulfamethoxazole	16	14	-	2	39	39	-	-	95.12%
Vancomycin	14	13	-	1	41	41	-	-	98.78%

Organism present in specimen SUS-6: *Staphylococcus aureus*.

¹ This is an ungraded challenge due to less than 80% participant consensus.

PARASITOLOGY (PA Specimens)

Specimen PA-6

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Ascaris lumbricoides eggs	1	100%	Unacceptable

Parasite present in specimen PA-6: *Entamoeba histolytica*.

Specimen PA-7

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Protozoan seen but no ID	1	100%	Acceptable

Parasite present in specimen PA-7: *Giardia lamblia*.

Specimen PA-8

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Protozoan seen but no ID	3	50.00%	Not graded
No parasite seen	1	16.67%	
Cryptosporidium sp., oocysts	1	16.67%	
Isospora belli oocysts	1	16.67%	

Parasites present in specimen PA-8: *Iodamoeba butschilli* and *Cryptosporidium sp. oocysts*. This is an ungraded challenge due to less than 80% participant consensus.

Specimen PA-9

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	5	100%	Acceptable

Parasite present in specimen PA-9: No parasite seen.

Specimen PA-10

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Strongyloides stercoralis larvae	4	80.00%	Acceptable
Parasite larva seen but no ID	1	20.00%	

Parasite present in specimen PA-10: *Strongyloides stercoralis larvae*.

PARASITOLOGY (FP Specimens)

Specimen FP-6

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Ascaris lumbricoides eggs	114	69.94%	Acceptable
Trichuris trichiura eggs	18	11.04%	Acceptable
No parasite seen	11	6.75%	
Entamoeba coli	3	1.84%	
Blastocystis hominis	3	1.84%	
Endolimax nana	2	1.23%	
Protozoan seen but no ID	2	1.23%	
Parasite egg seen but no ID	2	1.23%	
Hookworm	2	1.23%	
Iodamoeba butschlii	1	0.61%	
Parasite larva seen but no ID	1	0.61%	
Entamoeba histolytica	1	0.61%	
Fasciola hepatica eggs	1	0.61%	
Giardia lamblia	1	0.61%	
Clonorchis sinensis	1	0.61%	

Parasites present in specimen FP-6: *Ascaris lumbricoides* eggs and *Trichuris trichiura* eggs.

Specimen FP-7

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	120	92.31%	Acceptable
Endolimax nana	7	5.38%	
Trichuris trichiura eggs	1	0.77%	
Other parasite seen but no ID	1	0.77%	
Ascaris lumbricoides eggs	1	0.77%	
Entamoeba hartmanni	1	0.56%	

Parasite present in specimen FP-7: No parasite seen.

Specimen FP-8

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Taenia sp. eggs	102	50.25%	Acceptable
Blastocystis hominis	65	32.02%	Acceptable
Other parasite seen but no ID	1	0.49%	Acceptable
Endolimax nana	8	3.94%	
Ascaris lumbricoides eggs	5	2.46%	
No parasite seen	5	2.46%	
Strongyloides stercoralis larvae	4	1.97%	
Entamoeba coli	4	1.97%	
Hymenolepis diminuta eggs	1	0.49%	
Hymenolepis nana eggs	1	0.49%	
Iodamoeba butschlii	1	0.49%	
Paragonimus westermani eggs	1	0.49%	
Schistosoma mansoni eggs	1	0.49%	
Entamoeba histolytica	1	0.49%	
Enterobius vermicularis eggs	1	0.49%	
Chilomastix mesnili	1	0.49%	

Parasites present in specimen FP-8: *Taenia sp.* eggs and *Blastocystis hominis*.

PARASITOLOGY (FP Specimens)

Specimen FP-9

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Giardia lamblia	122	84.14%	Acceptable
No parasite seen	9	6.21%	
Taenia sp. eggs	2	1.38%	
Trichuris trichiura eggs	1	0.69%	
Parasite egg seen but no ID	1	0.69%	
Hymenolepis nana eggs	1	0.69%	
Isospora belli oocysts	1	0.69%	
Sarcocystis sp. oocysts	1	0.69%	
Schistosoma sp. eggs, NOS	1	0.69%	
Strongyloides stercoralis larvae	1	0.69%	
Ascaris lumbricoides eggs	1	0.69%	
Blastocystis hominis	1	0.69%	
Chilomastix mesnili	1	0.69%	
Endolimax nana	1	0.69%	
Enterobius vermicularis eggs	1	0.69%	

Parasite present in specimen FP-9: *Giardia lamblia*.

Specimen FP-10

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Plasmodium ovale	12	9.02%	Not graded
Plasmodium sp., not falciparum	4	3.01%	
No parasite seen	56	42.11%	
Plasmodium vivax	38	28.57%	
Plasmodium sp., NOS	14	10.53%	
Plasmodium malariae	5	3.76%	
Plasmodium falciparum	3	2.26%	
Leishmania sp.	1	0.75%	

Parasite present in specimen FP-10: *Plasmodium ovale*. This is an ungraded challenge due to less than 80% participant consensus.

Syphilis Serology—Qualitative: VDRL Slide

<u>Method</u>	Specimen SY-6			Specimen SY-7			Specimen SY-8		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non- Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non- Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non- Reactive</u>
ALL METHODS	8	-	1	9	-	-	-	-	9
BioBacter	1	-	-	1	-	-	-	-	1
Biokit	1	-	-	1	-	-	-	-	1
bioMerieux	-	-	1	1	-	-	-	-	1
Omega Diagnostics	1	-	-	1	-	-	-	-	1
Wiener Lab	4	-	-	4	-	-	-	-	4

<u>Method</u>	Specimen SY-9			Specimen SY-10		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non- Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non- Reactive</u>
ALL METHODS	9	-	-	1	-	8
BioBacter	1	-	-	-	-	1
Biokit	1	-	-	-	-	1
bioMerieux	1	-	-	1	-	-
Omega Diagnostics	1	-	-	-	-	1
Wiener Lab	4	-	-	-	-	4

Syphilis Serology—Quantitative: VDRL Slide Titer

<u>Specimen/Method</u>	<u>0 dils</u>	<u>1 dil</u>	<u>2 dils</u>	<u>4 dils</u>	<u>8 dils</u>	<u>16 dils</u>	<u>32 dils</u>	<u>>32 dils</u>
Specimen SY-6								
ALL METHODS	-	-	-	4	1	1	-	-
BioBacter	-	-	-	1	-	-	-	-
Omega Diagnostics	-	-	-	1	-	-	-	-
Wiener Lab	-	-	-	2	1	1	-	-
Specimen SY-7								
ALL METHODS	-	-	1	2	3	-	-	-
BioBacter	-	-	1	-	-	-	-	-
Omega Diagnostics	-	-	-	-	1	-	-	-
Wiener Lab	-	-	-	2	2	-	-	-
Specimen SY-9								
ALL METHODS	-	-	-	4	2	-	-	-
BioBacter	-	-	-	1	-	-	-	-
Omega Diagnostics	-	-	-	1	-	-	-	-
Wiener Lab	-	-	-	2	2	-	-	-

Syphilis Serology—Qualitative: MHA-TP

<u>Method</u>	Specimen SY-6		Specimen SY-7		Specimen SY-8	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	9	1	10	-	-	10
Biokit	1	-	1	-	-	1
Serodia	7	-	7	-	-	7
	Specimen SY-9		Specimen SY-10			
ALL METHODS	10	-	1	9		
Biokit	1	-	-	1		
Serodia	7	-	-	7		

Syphilis Serology—Qualitative: FTA-ABS (*Treponema pallidum* Antibodies)

<u>Method</u>	Specimen SY-6		Specimen SY-7		Specimen SY-8	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	3	-	3	-	-	3
bioMerieux	2	-	2	-	-	2
	Specimen SY-9		Specimen SY-10			
ALL METHODS	3	-	-	3		
bioMerieux	2	-	-	2		

Syphilis Serology—Qualitative: RPR

<u>Method</u>	Specimen SY-6		Specimen SY-7		Specimen SY-8	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	17	2	18	1	1	18
Abbott Syfacard-R	2	-	2	-	-	2
Becton Dickinson	2	-	2	-	-	2
bioMerieux	3	1	4	-	-	4
Immunostics Inc.	1	-	1	-	-	1
Omega Diagnostics	5	-	5	-	1	4
Serodia	1	-	1	-	-	1
SPINREACT	1	-	1	-	-	1
Wiener Lab	1	-	1	-	-	1
	Specimen SY-9		Specimen SY-10			
ALL METHODS	18	1	2	17		
Abbott Syfacard-R	2	-	-	2		
Becton Dickinson	2	-	-	2		
bioMerieux	4	-	1	3		
Immunostics Inc.	1	-	-	1		
Omega Diagnostics	5	-	1	4		
Serodia	1	-	-	1		
SPINREACT	1	-	-	1		
Wiener Lab	1	-	-	1		

Syphilis Serology—Quantitative: RPR (Titer)

<u>Specimen/Method</u>	<u>1</u>	<u>2</u>	<u>4</u>	<u>8</u>	<u>16</u>	<u>32</u>	<u>64</u>	<u>>64</u>
Specimen SY-6								
ALL METHODS	-	4	5	1	1	-	1	1
Abbott Syfacard-R	-	2	-	-	-	-	-	-
Becton Dickinson	-	1	-	-	-	-	-	-
bioMerieux	-	-	2	1	-	-	-	-
Immunostics Inc.	-	-	1	-	-	-	-	-
Omega Diagnostics	-	-	-	-	1	-	-	-
Serodia	-	-	-	-	-	-	1	1
SPINREACT	-	-	1	-	-	-	-	-
Wiener Lab	-	-	1	-	-	-	-	-
Specimen SY-7								
ALL METHODS	1	5	3	1	2	-	-	1
Abbott Syfacard-R	-	2	-	-	-	-	-	-
Becton Dickinson	-	1	-	-	-	-	-	-
bioMerieux	-	-	2	1	-	-	-	-
Immunostics Inc.	-	1	-	-	-	-	-	-
Omega Diagnostics	-	-	-	-	1	-	-	-
Serodia	-	-	-	-	1	-	-	1
SPINREACT	-	-	1	-	-	-	-	-
Wiener Lab	-	1	-	-	-	-	-	-
Specimen SY-9								
ALL METHODS	-	2	7	2	-	-	-	2
Abbott Syfacard-R	-	1	1	-	-	-	-	-
Becton Dickinson	-	-	1	-	-	-	-	-
bioMerieux	-	-	2	1	-	-	-	-
Immunostics Inc.	-	-	1	-	-	-	-	-
Omega Diagnostics	-	-	-	1	-	-	-	-
Serodia	-	-	-	-	-	-	-	2
SPINREACT	-	-	1	-	-	-	-	-
Wiener Lab	-	-	1	-	-	-	-	-

Viral Markers – Anti-HBc

<u>Method</u>	Specimen VM-6		Specimen VM-7		Specimen VM-8	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	52	-	52	51	1
Abbott Architect - IgM	-	1	-	1	1	-
Abbott Architect - Total	-	3	-	3	3	-
Abbott AxSYM - IgG	-	2	-	2	2	-
Abbott AxSYM - IgM	-	3	-	3	3	-
Abbott AxSYM - Total	-	15	-	15	14	1
Abbott IMx - Total	-	2	-	2	2	-
bioMerieux Vidas - Total	-	2	-	2	2	-
DiaSorin - Total	-	1	-	1	1	-
Other IgG Method	-	1	-	1	1	-
Other Total Method	-	4	-	4	4	-
Roche Elecsys - IgM	-	2	-	2	2	-
Roche Elecsys - Total	-	6	-	6	6	-
Roche Elecsys 1010/2010	-	1	-	1	1	-
VITROS Eci - Total	-	6	-	6	6	-
	Specimen VM-9		Specimen VM-10			
ALL METHODS	-	52	-	52		
Abbott Architect - IgM	-	1	-	1		
Abbott Architect - Total	-	3	-	3		
Abbott AxSYM - IgG	-	2	-	2		
Abbott AxSYM - IgM	-	3	-	3		
Abbott AxSYM - Total	-	15	-	15		
Abbott IMx - Total	-	2	-	2		
bioMerieux Vidas - Total	-	2	-	2		
DiaSorin - Total	-	1	-	1		
Other IgG Method	-	1	-	1		
Other Total Method	-	4	-	4		
Roche Elecsys - IgM	-	2	-	2		
Roche Elecsys - Total	-	6	-	6		
Roche Elecsys 1010/2010	-	1	-	1		
VITROS Eci - Total	-	6	-	6		

Viral Markers – Anti-HIV

<u>Method</u>	Specimen VM-6		Specimen VM-7		Specimen VM-8	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	64	-	64	-	64
Abbott Architect - IgG	-	1	-	1	-	1
Abbott Architect - IgM	-	1	-	1	-	1
Abbott Architect - Total	-	5	-	5	-	5
Abbott AxSYM - IgG	-	2	-	2	-	2
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	14	-	14	-	14
Bayer ADVIA Centaur - Total	-	2	-	2	-	2
bioMerieux Vidas - Total	-	9	-	9	-	9
Bio-Rad Evolis	-	1	-	1	-	1
Orasure OraQuick Advance Rapid HIV-1/2	-	1	-	1	-	1
Other IgG Method	-	1	-	1	-	1
Other Total Method	-	7	-	7	-	7
Roche Elecsys - Total	-	10	-	10	-	10
Roche Elecsys 1010/2010	-	1	-	1	-	1
VITROS Eci - Total	-	4	-	4	-	4

	Specimen VM-9		Specimen VM-10	
ALL METHODS	1	63	1	63
Abbott Architect - IgG	-	1	-	1
Abbott Architect - IgM	-	1	-	1
Abbott Architect - Total	-	5	-	5
Abbott AxSYM - IgG	-	2	-	2
Abbott AxSYM - IgM	-	1	-	1
Abbott AxSYM - Total	1	13	-	14
Bayer ADVIA Centaur - Total	-	2	1	1
bioMerieux Vidas - Total	-	9	-	9
Bio-Rad Evolis	-	1	-	1
Orasure OraQuick Advance Rapid HIV-1/2	-	1	-	1
Other IgG Method	-	1	-	1
Other Total Method	-	7	-	7
Roche Elecsys - Total	-	10	-	10
Roche Elecsys 1010/2010	-	1	-	1
VITROS Eci - Total	-	4	-	4

Viral Markers – HAV

<u>Method</u>	Specimen VM-6		Specimen VM-7		Specimen VM-8	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	1	44	1	44	1	44
Abbott Architect - IgG	-	3	-	3	-	3
Abbott AxSYM - IgG	-	4	-	4	-	4
Abbott AxSYM - IgM	-	5	-	5	-	5
Abbott AxSYM - Total	-	6	-	6	-	6
bioMerieux Vidas - IgM	-	8	-	8	-	8
bioMerieux Vidas - Total	-	1	-	1	-	1
DiaSorin - IgM	-	1	-	1	-	1
Other IgG Method	-	1	-	1	-	1
Roche Elecsys - IgG	-	1	-	1	-	1
Roche Elecsys - IgM	-	7	-	7	-	7
Roche Elecsys - Total	1	4	1	4	1	4
VITROS ECI - IgM	-	1	-	1	-	1

	Specimen VM-9		Specimen VM-10	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	21	23	23	22
Abbott Architect - IgG	2	1	3	-
Abbott AxSYM - IgG	4	-	4	-
Abbott AxSYM - IgM	-	5	-	5
Abbott AxSYM - Total	5	1	6	-
bioMerieux Vidas - IgM	-	8	-	8
bioMerieux Vidas - Total	1	-	1	-
DiaSorin - IgM	-	1	-	1
Other IgG Method	1	-	1	-
Roche Elecsys - IgG	1	-	1	-
Roche Elecsys - IgM	-	6	-	7
Roche Elecsys - Total	5	-	5	-
VITROS ECI - IgM	-	1	-	1

Viral Markers – HBeAg

<u>Method</u>	Specimen VM-6		Specimen VM-7		Specimen VM-8	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	27	-	27	26	-
Abbott AxSYM - IgG	-	1	-	1	1	-
Abbott AxSYM - Total	-	8	-	8	8	-
bioMerieux Vidas - IgG	-	1	-	1	1	-
bioMerieux Vidas - Total	-	2	-	2	2	-
Dade Behring BEP 2000	-	1	-	1	1	-
DiaSorin - Total	-	1	-	1	1	-
Other IgG Method	-	1	-	1	1	-
Other Total Method	-	2	-	2	2	-
Roche Elecsys - Total	-	4	-	4	4	-
VITROS ECi - Total	-	3	-	3	2	-
	Specimen VM-9		Specimen VM-10			
ALL METHODS	-	26	-	26		
Abbott AxSYM - IgG	-	1	-	1		
Abbott AxSYM - Total	-	8	-	8		
bioMerieux Vidas - IgG	-	1	-	1		
bioMerieux Vidas - Total	-	2	-	2		
Dade Behring BEP 2000	-	1	-	1		
DiaSorin - Total	-	1	-	1		
Other IgG Method	-	1	-	1		
Other Total Method	-	2	-	2		
Roche Elecsys - Total	-	4	-	4		
VITROS ECi - Total	-	2	-	2		

Viral Markers – HBsAb

<u>Method</u>	Specimen VM-6		Specimen VM-7		Specimen VM-8	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	47	-	47	1	46
Abbott Architect - IgG	-	1	-	1	-	1
Abbott Architect - Total	-	3	-	3	-	3
Abbott AxSYM	-	1	-	1	-	1
Abbott AxSYM - IgG	-	3	-	3	-	3
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	10	-	10	-	10
bioMerieux Vidas - IgG	-	1	-	1	-	1
bioMerieux Vidas - Total	-	2	-	2	-	2
DiaSorin - Total	-	1	-	1	-	1
Other IgG Method	-	1	-	1	-	1
Other Total Method	-	3	-	3	-	3
Roche Elecsys - IgG	-	2	-	2	-	2
Roche Elecsys - Total	-	8	-	8	-	8
Roche Elecsys 1010/2010	-	1	-	1	-	1
VITROS ECI - Total	-	4	-	4	1	3
	Specimen VM-9		Specimen VM-10			
ALL METHODS	-	47	-	47		
Abbott Architect - IgG	-	1	-	1		
Abbott Architect - Total	-	3	-	3		
Abbott AxSYM	-	1	-	1		
Abbott AxSYM - IgG	-	3	-	3		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	10	-	10		
bioMerieux Vidas - IgG	-	1	-	1		
bioMerieux Vidas - Total	-	2	-	2		
DiaSorin - Total	-	1	-	1		
Other IgG Method	-	1	-	1		
Other Total Method	-	3	-	3		
Roche Elecsys - IgG	-	2	-	2		
Roche Elecsys - Total	-	8	-	8		
Roche Elecsys 1010/2010	-	1	-	1		
VITROS ECI - Total	-	4	-	4		

Viral Markers – HCV

<u>Method</u>	Specimen VM-6		Specimen VM-7		Specimen VM-8	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	57	-	57	7	50
Abbott Architect - IgG	-	2	-	2	-	2
Abbott Architect - IgM	-	1	-	1	-	1
Abbott Architect - Total	-	6	-	6	-	6
Abbott AxSYM - IgG	-	3	-	3	1	2
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	13	-	13	4	9
Abbott IMx - Total	-	2	-	2	2	-
Bayer ADVIA Centaur - Total	-	3	-	3	-	3
Dade Behring BEP 2000	-	1	-	1	-	1
Other IgG Method	-	1	-	1	-	1
Other Total Method	-	8	-	8	-	8
Roche Elecsys - Total	-	3	-	3	-	3
VITROS ECi - IgG	-	1	-	1	-	1
VITROS ECi - Total	-	6	-	6	-	6
	Specimen VM-9		Specimen VM-10			
ALL METHODS	56	1	57	-		
Abbott Architect - IgG	2	-	2	-		
Abbott Architect - IgM	1	-	1	-		
Abbott Architect - Total	6	-	6	-		
Abbott AxSYM - IgG	3	-	3	-		
Abbott AxSYM - IgM	1	-	1	-		
Abbott AxSYM - Total	13	-	13	-		
Abbott IMx - Total	2	-	2	-		
Bayer ADVIA Centaur - Total	3	-	3	-		
Dade Behring BEP 2000	1	-	1	-		
Other IgG Method	1	-	1	-		
Other Total Method	7	1	8	-		
Roche Elecsys - Total	3	-	3	-		
VITROS ECi - IgG	1	-	1	-		
VITROS ECi - Total	6	-	6	-		

Blood Gases – pH

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	18	7.157	0.012	0.2	7.16	18	7.572	0.021	0.3	7.56
AVL OMNI	10	7.153	0.013	0.2	7.16	10	7.558	0.006	0.1	7.56
<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	18	6.878	0.020	0.3	6.88	18	7.166	0.009	0.1	7.17
AVL OMNI	10	6.887	0.021	0.3	6.89	10	7.166	0.011	0.2	7.17
<u>Method</u>	Specimen BG-10									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	18	7.409	0.014	0.2	7.41					
AVL OMNI	10	7.400	0.008	0.1	7.40					

Blood Gases - pCO₂ (mmHg)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	18	71.81	3.10	4.3	71.4	17	23.03	1.07	4.7	23.2
AVL OMNI	10	72.76	3.07	4.2	71.7	10	23.63	0.76	3.2	23.9
<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	18	89.29	3.88	4.3	88.6	18	58.51	2.06	3.5	58.5
AVL OMNI	10	88.17	2.82	3.2	88.5	10	58.64	1.90	3.2	58.7
<u>Method</u>	Specimen BG-10									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	18	44.03	1.94	4.4	44.2					
AVL OMNI	10	44.04	0.99	2.3	44.3					

Blood Gases - pO₂ (mmHg)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	18	68.19	16.30	23.9	73.5	18	140.22	6.45	4.6	139.3
AVL OMNI	10	75.37	15.36	20.4	80.6	10	140.02	4.22	3.0	139.2
<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	18	39.71	23.79	59.9	47.4	18	108.62	11.49	10.6	113.4
AVL OMNI	10	49.72	24.45	49.2	61.5	10	113.70	10.16	8.9	117.9
<u>Method</u>	Specimen BG-10									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	18	98.96	9.84	9.9	101.1					
AVL OMNI	10	101.98	9.35	9.2	106.0					

Blood Gases - Ionized Calcium (mmol/L)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	12	2.480	1.902	76.7	1.47	12	0.813	0.625	76.9	0.50
AVL OMNI	6	3.527	2.308	65.5	5.57	6	1.163	0.750	64.5	1.77

Blood Gases - Chloride (mmol/L)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	74.9	3.0	4.0	75	7	117.1	3.4	2.9	116
AVL OMNI	6	74.8	3.3	4.4	75	6	116.5	3.3	2.8	116

<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	67.0	3.5	5.2	66	7	87.3	3.0	3.4	87
AVL OMNI	6	67.0	3.8	5.7	66	6	87.0	3.2	3.6	87

<u>Method</u>	Specimen BG-10				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	94.7	3.5	3.7	93
AVL OMNI	6	94.2	3.5	3.7	93

Blood Gases - Potassium (mmol/L)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	1.74	0.10	5.6	1.8	10	6.31	0.06	0.9	6.3
AVL OMNI	6	1.72	0.12	6.8	1.7	6	6.30	0.00	0.0	6.3

<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	11.09	0.53	4.8	11.2	10	3.17	0.08	2.6	3.2
AVL OMNI	6	11.08	0.35	3.1	11.2	6	3.17	0.10	3.3	3.1

<u>Method</u>	Specimen BG-10				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	4.25	0.05	1.2	4.3
AVL OMNI	6	4.23	0.05	1.2	4.2

Blood Gases - Sodium (mmol/L)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	109.3	5.1	4.7	111	10	152.6	5.3	3.5	155
AVL OMNI	6	112.0	1.3	1.1	113	6	155.7	1.0	0.7	156

<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	84.5	3.6	4.2	86	10	130.2	2.4	1.9	131
AVL OMNI	6	86.8	0.8	0.9	87	6	131.8	1.2	0.9	132

<u>Method</u>	Specimen BG-10				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	130.4	2.8	2.1	132
AVL OMNI	6	132.3	0.8	0.6	133

Medical Laboratory Evaluation

25 Massachusetts Ave NW Ste 700

Washington, DC 20001-7401

800-338-2746 • 202-261-4500 • Fax: 202-835-0440

www.acponline.org/mle